PLEASANTON, Calif., April 17, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Bayer, Genentech, Novo Nordisk, Takeda, and others will be among the keynote speakers at the 2024 Veeva Commercial Summit, May 7-8 in Boston. Commercial and medical affairs professionals will share how they are innovating across content, data and analytics, and customer interactions to advance the future of customer-centric engagement.
Veeva CEO Peter Gassner will headline the opening keynote, sharing how the recent delivery of Veeva Vault CRM fits into Veeva's commercial vision. Attendees will see the first demo of Veeva Vault CRM Campaign Manager, as well as a demo of advancements in modern data and connected software with Veeva Compass.
Leading and emerging biopharmas will headline the keynotes, with topics including:
"To be truly customer-centric in today's increasingly complex environment requires even greater alignment and collaboration across sales, marketing, and medical," said Paul Shawah, executive vice president at Veeva. "Veeva is committed to commercial execution and bringing life sciences leaders together to share learnings and fresh ideas around commercial strategies and customer engagement to move the industry forward."
One of the largest industry events in North America for commercial and medical affairs professionals, Veeva Commercial Summit will host over 1,700 leaders across more than 100 sessions. Life sciences industry professionals can register and see the full agenda and program details at veeva.com/Summit.
Additional Information
For more on Veeva Commercial Summit, visit: veeva.com/Summit
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Alison Borris
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$215.95 |
Daily Change: | -4.71 -2.13 |
Daily Volume: | 1,165,694 |
Market Cap: | US$35.060B |
January 13, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load